Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Patient frailty not a key factor when choosing between TAVR and SAVR

Frailty measurements may still provide helpful information in other ways, of course. 

What new research tells us about TAVR and platelet-to-lymphocyte ratios

The blood-based biomarker was previously associated with worse acute coronary syndrome outcomes. What does it mean for TAVR patients?

Thumbnail

New risk calculator detects TEER patients who may need to be readmitted for HF

Once the tool's performance is properly validated, it could help clinicians deliver better patient care and result in significant cost savings for health systems.

Thumbnail

How the presence of AFib can impact TAVR, SAVR outcomes

AVR patients may require a longer hospitalization if they present with pre-existing or new-onset AFib.

Life expectancy lower among SAVR patients than the general public

Should patients be undergoing SAVR earlier? Is poor follow-up care partially to blame? 

Thumbnail

TMVR with transfemoral access a 'promising option,’ early data suggest

Researchers reported at TCT 2021 that survival was 100% after 30 days.

Thumbnail

5 years later, TAVR still delivering strong results for intermediate-risk patients

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years. 

Thumbnail

TAVR more cost-effective than surgery for low-risk patients, new 2-year study confirms

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.